CLINICAL TRIALS PROFILE FOR THIOTHIXENE
✉ Email this page to a colleague
All Clinical Trials for thiothixene
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01234454 ↗ | Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI | Completed | University of North Carolina, Chapel Hill | N/A | 2002-01-01 | The general aim is to compare the effects of typical and atypical antipsychotic medication on brain structure and function. A parallel group treatment trial will be utilized to compare the effects of the typical antipsychotic thiothixene versus the atypical antipsychotics risperidone (RIS) and olanzapine (OLZ) on brain structure and function in schizophrenia in an effort to determine the neuroanatomic basis for cognitive pathology in schizophrenia and its amelioration by atypical antipsychotic drugs. |
| NCT02582736 ↗ | Antipsychotics and Risk of Hyperglycemic Emergencies | Completed | Canadian Institutes of Health Research (CIHR) | 2012-04-01 | The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs. | |
| NCT02582736 ↗ | Antipsychotics and Risk of Hyperglycemic Emergencies | Completed | Drug Safety and Effectiveness Network, Canada | 2012-04-01 | The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for thiothixene
Condition Name
Clinical Trial Locations for thiothixene
Trials by Country
Clinical Trial Progress for thiothixene
Clinical Trial Phase
Clinical Trial Sponsors for thiothixene
Sponsor Name
| Sponsor Name for thiothixene | |
| Sponsor | Trials |
| Canadian Institutes of Health Research (CIHR) | 1 |
| Drug Safety and Effectiveness Network, Canada | 1 |
| Canadian Network for Observational Drug Effect Studies, CNODES | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
